Non-alcoholic fatty liver disease (NAFLD) is characterized by an accumulation of fat in the liver, termed steatosis. Non-alcoholic steatohepatitis (NASH) occurs when steatosis progresses, causing inflammation and liver tissue injury, which can lead to hepatocyte death, fibrosis, inflammation, and scarring (cirrhosis). NAFLD is the most prevalent chronic liver disease in the United States, affecting approximately 25% of adults.
DiaPharma offers a diverse portfolio of ELISA assays for measuring blood-based biomarkers in liver research studies. Utilization of these biomarkers provides a non-invasive and accessible testing option to assess liver function and evaluate NAFLD and NASH disease mechanisms. These biomarkers are currently being investigated to further understand the pathogenesis of NAFLD and NASH liver diseases and to evaluate response to treatment in clinical trial and research settings. Read more details…